New x-ray activated drug injection tested for Hard-to-Treat cancers

NCT ID NCT04389281

Recruiting now Disease control Sponsor: Immunolight, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a treatment called X-PACT for people with advanced head and neck cancer, breast cancer, soft tissue sarcoma, or melanoma that has not responded to standard treatments. X-PACT involves injecting a drug called methoxsalen directly into the tumor and then activating it with a targeted X-ray beam. The main goal is to check if the treatment is safe, with up to 52 participants receiving multiple injections over several weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: X-PACT (methoxsalen injection plus X-ray activation)
What this could lead to: If it works, this could point toward a new local treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early Phase 1 trial with only 52 participants, focused on safety. It may not show meaningful tumor shrinkage, and there are risks from the injection and X-ray exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma cancer cutaneous melanoma head and neck cancer Head and Neck Neoplasms metastatic melanoma soft tissue sarcoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR CANCER

Contacts and locations

Locations

Duke University
RECRUITING

Durham, North Carolina, 27710, United States
Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States
Prisma Health
RECRUITING

Greenville, South Carolina, 29605, United States
Sibley Hospital - Johns Hopkins University
RECRUITING

Washington D.C., District of Columbia, 20016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.